Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for TMO and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for TMO and 80,000+ other tickers.
See exactly how TMO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for TMO and 80,000+ other tickers.
Thermo Fisher Scientific Inc. is a global leader in scientific services, providing a comprehensive range of offerings that include life sciences solutions, advanced analytical instruments, specialized diagnostic products, and an extensive portfolio of laboratory supplies and biopharmaceutical services. The company's reach extends across North America, Europe, Asia-Pacific, and other international markets. Its Life Sciences Solutions division furnishes researchers with essential reagents, state-of-the-art instruments, and consumables vital for biological and medical exploration, the…
Thermo Fisher Scientific is eyeing a 15%-20% increase in its customer base in India over the next five years, betting on the growing biopharma research and manufacturing ecosystem, the head of its India unit said.
Thermo Fisher Scientific Inc. TMO raised its 2026 outlook after second-quarter earnings and revenues exceeded expectations. The update reflects stronger customer activity, better acquisition performance and improved operating leverage.
Examine the evolution of Thermo Fisher's (TMO) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
Argent Capital Management LLC trimmed its holdings in shares of Thermo Fisher Scientific Inc. (NYSE: TMO) by 35.8% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 33,602 shares of the medical research company's stock after selling 18,757 shares during the quarter.
TMO is expanding bioproduction, AI tools and clinical data capabilities, but execution will be key as competition intensifies.